You are here

New Drug Approved to Treat Glaucoma

The drug, whose active ingredient is tafluprost, was previously approved for use in certain European countries under the brand Saflutan. Merck had proposed to use that brand name in the U.S., but the brand wasn't accepted by the FDA, causing the change to Zioptan.

Merck said Zioptan is the first preservative-free prostaglandin analog ophthalmic solution. Preservatives used with some glaucoma drugs can be associated with certain adverse events.

In clinical trials, Zioptan lowered intraocular pressure after three and six months of use, Merck said.

Read the full article in the Wall Street Journal.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs